340 related articles for article (PubMed ID: 23994499)
1. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.
Ayala-Nuñez NV; Jarupathirun P; Kaptein SJ; Neyts J; Smit JM
Antiviral Res; 2013 Oct; 100(1):238-45. PubMed ID: 23994499
[TBL] [Abstract][Full Text] [Related]
2. Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.
Wang M; Yang F; Huang D; Huang Y; Zhang X; Wang C; Zhang S; Zhang R
Front Cell Infect Microbiol; 2017; 7():157. PubMed ID: 28536674
[TBL] [Abstract][Full Text] [Related]
3. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
[TBL] [Abstract][Full Text] [Related]
4. Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan.
Piccini LE; Carro AC; Quintana VM; Damonte EB
Virus Res; 2020 Dec; 290():198150. PubMed ID: 32866533
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
6. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
7. Narasin, a novel antiviral compound that blocks dengue virus protein expression.
Low JS; Wu KX; Chen KC; Ng MM; Chu JJ
Antivir Ther; 2011; 16(8):1203-18. PubMed ID: 22155902
[TBL] [Abstract][Full Text] [Related]
8. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro.
Kaptein SJ; De Burghgraeve T; Froeyen M; Pastorino B; Alen MM; Mondotte JA; Herdewijn P; Jacobs M; de Lamballerie X; Schols D; Gamarnik AV; Sztaricskai F; Neyts J
Antimicrob Agents Chemother; 2010 Dec; 54(12):5269-80. PubMed ID: 20837762
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses.
Flipse J; Diosa-Toro MA; Hoornweg TE; van de Pol DP; Urcuqui-Inchima S; Smit JM
Sci Rep; 2016 Jul; 6():29201. PubMed ID: 27380892
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy.
Huang X; Yue Y; Li D; Zhao Y; Qiu L; Chen J; Pan Y; Xi J; Wang X; Sun Q; Li Q
Sci Rep; 2016 Feb; 6():22303. PubMed ID: 26923481
[TBL] [Abstract][Full Text] [Related]
11. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus.
Soto-Acosta R; Bautista-Carbajal P; Syed GH; Siddiqui A; Del Angel RM
Antiviral Res; 2014 Sep; 109():132-40. PubMed ID: 25017471
[TBL] [Abstract][Full Text] [Related]
12. Peptide inhibitors against dengue virus infection.
Panya A; Bangphoomi K; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2014 Aug; 84(2):148-57. PubMed ID: 24612829
[TBL] [Abstract][Full Text] [Related]
13. 3',5'Di-O-trityluridine inhibits in vitro flavivirus replication.
De Burghgraeve T; Selisko B; Kaptein S; Chatelain G; Leyssen P; Debing Y; Jacobs M; Van Aerschot A; Canard B; Neyts J
Antiviral Res; 2013 May; 98(2):242-7. PubMed ID: 23470860
[TBL] [Abstract][Full Text] [Related]
14. Dengue virus isolation relying on antibody-dependent enhancement mechanism using FcγR-expressing BHK cells and a monoclonal antibody with infection-enhancing capacity.
Moi ML; Lim CK; Tajima S; Kotaki A; Saijo M; Takasaki T; Kurane I
J Clin Virol; 2011 Nov; 52(3):225-30. PubMed ID: 21824813
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus.
Ito M; Mukai RZ; Takasaki T; Kotaki A; Kurane I
Arch Virol; 2010 Oct; 155(10):1617-24. PubMed ID: 20644969
[TBL] [Abstract][Full Text] [Related]
16. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro.
Nicholson CO; Costin JM; Rowe DK; Lin L; Jenwitheesuk E; Samudrala R; Isern S; Michael SF
Antiviral Res; 2011 Jan; 89(1):71-4. PubMed ID: 21093488
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.
Goncalvez AP; Engle RE; St Claire M; Purcell RH; Lai CJ
Proc Natl Acad Sci U S A; 2007 May; 104(22):9422-7. PubMed ID: 17517625
[TBL] [Abstract][Full Text] [Related]
18. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells.
Chareonsirisuthigul T; Kalayanarooj S; Ubol S
J Gen Virol; 2007 Feb; 88(Pt 2):365-375. PubMed ID: 17251552
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
Acosta EG; Bartenschlager R
Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection.
Chan CYY; Low JZH; Gan ES; Ong EZ; Zhang SL; Tan HC; Chai X; Ghosh S; Ooi EE; Chan KR
mSphere; 2019 Sep; 4(5):. PubMed ID: 31533998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
